Long-term complications of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990-2020
Authors:
Preprint
- 2 September 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Information on sequelae of Shiga toxin-producing Escherichia coli (STEC) O157 infection is limited to short-term follow-up of paediatric haemolytic uraemic syndrome (HUS) cases. We investigate recorded long-term health outcomes experienced by individuals exposed to STEC O157 and STEC-HUS up to three decades on.Methods We compared acute or new onset of chronic outcomes in individuals ≥ 1 year after STEC O157 or STEC-HUS to unexposed general population comparators between 01/01/1990-01/01/2019. The unexposed were their age- and sex-equivalents (4:1 matching ratio) and assigned the same study entry date. Outcomes were identified in primary and secondary care and categorised as renal, neurological, cardiac, gastrointestinal, respiratory, or endocrine. Hazard ratios (HRs) and 95% confidence intervals (95%CI) were calculated using Cox regression.Results Of 1,245 individuals with STEC O157, 65 developed HUS (5.2%). Individuals with STEC O157 were more likely to experience renal (adjusted (a)HR: 1.9, 95%CI: 1.1–3.3), gastrointestinal (aHR: 1.7, 95%CI: 1.2–2.6) and respiratory (aHR: 1.3, 95%CI: 1.2–1.5) outcomes compared to the unexposed, on average between 3.4–11 years after exposure. Gastrointestinal (HR: 7.7, 95%CI: 2.6–23), renal (HR: 5.5, 95%CI: 1.6–19), cardiac (HR: 5.1, 95%CI: 1.1–23) and respiratory (HR: 1.9, 95%CI: 1.1–3.1) outcomes were more common in the STEC-HUS cohort and occurred sooner, on average after 2.7–4.8 years.Conclusions Long-term complications were nearly twice as likely in the STEC O157 cohort, and as many as eight times more likely following STEC-HUS. We recommend that those exposed to STEC be monitored for at least five years for late-emerging renal and extrarenal complications.Keywords
All Related Versions
- Version 1, 2024-09-02, Research Square
- Published version: Pediatric Nephrology, 40 (7), 2295.
This publication has 31 references indexed in Scilit:
- Validating epilepsy diagnoses in routinely collected dataSeizure: European Journal of Epilepsy, 2017
- Long-term outcomes of Shiga toxin hemolytic uremic syndromePediatric Nephrology, 2013
- Renal and neurological involvement in typical Shiga toxin-associated HUSNature Reviews Nephrology, 2012
- Epidemic Profile of Shiga-Toxin–ProducingEscherichia coliO104:H4 Outbreak in GermanyNew England Journal of Medicine, 2011
- Gastrointestinal Complications of Post-Diarrheal Hemolytic Uremic SyndromeEuropean Journal of Pediatric Surgery, 2007
- Absence of renal sequelae after childhood Escherichia coli O157:H7 gastroenteritisKidney International, 2006
- Non‐O157 Shiga Toxin–ProducingEscherichia coliInfections in the United States, 1983–2002The Journal of Infectious Diseases, 2005
- Long-term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic SyndromeJAMA, 2003
- Clinical Course and the Role of Shiga Toxin–ProducingEscherichia coliInfection in the Hemolytic‐Uremic Syndrome in Pediatric Patients, 1997–2000, in Germany and Austria: A Prospective StudyThe Journal of Infectious Diseases, 2002
- Cholelithiasis following Escherichia coli O157?:?H7-associated hemolytic uremic syndromePediatric Nephrology, 1998